Sunday, 16 January 2022

Tag Archives: BioNTech

Pfizer, BioNTech launch vaccine trial in kids under 12

NEW YORK – Pfizer Inc and German partner BioNTech SE began testing their Covid-19 vaccine in children under 12, with hopes of expanding vaccination to that age range by early 2022, the US drugmaker said on Thursday. The first volunteers in the early-stage trial were given their first injections on ...

Read More »

UK to introduce covid-19 vaccine next week

LONDON: Britain on Wednesday became the first Western country to approve a Covid-19 vaccine for general use, announcing a rollout of Pfizer-BioNTech’s drug from next week in a historic advance for humanity’s fightback against the coronavirus. “Help is on its way,” health secretary Matt Hancock tweeted as his department announced ...

Read More »

UK secures 90 million doses of potential coronavirus vaccines

LONDON: UK government said Monday it has secured access to 90 million doses of potential coronavirus vaccines in deals with biotech firms BioNTech, Pfizer and Valneva. Business Secretary Alok Sharma said Britain would now have access to three different types of vaccines being developed domestically and around the world, and ...

Read More »

UK, Germany Start Trials of COVID-19 Vaccine

BERLIN: The race to develop an effective vaccine against the novel coronavirus gathered pace this week, as clinical trials on humans were approved in Germany and launched in the UK. Though there are now around 150 development projects worldwide, the German and British plans are among only five clinical trials ...

Read More »

Sanofi to invest 80mn euros in BioNTech

FRANKFURT: French drugmaker Sanofi will invest 80 million euros ($90.9 million) in BioNTech and expand its collaboration with the German biotech group, BioNTech said on Friday. BioNTech, which first agreed a collaboration with Sanofi in 2015 in the area of cancer immunotherapy, did not specify the stake Sanofi would hold ...

Read More »

Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

Pfizer has agreed to pay German biotech firm BioNTech up to $425 million (£334.33 million) in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 ...

Read More »